### Learner Notification

**Society of Gynecologic Oncology**

**2022 ACCC Series #3 - Real-World Palliative Care in GYN Oncology**

**Enduring: July 27, 2022 – July 27, 2023**

**Online**

**Acknowledgement of Financial Commercial Support**

No financial commercial support was received for this educational activity.

**Acknowledgement of In-Kind Commercial Support**

No in-kind commercial support was received for this educational activity.

**Satisfactory Completion**

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety.  Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

**Accreditation Statement**

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Society of Gynecologic Oncology (SGO). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Physicians (ACCME) Credit Designation**

Amedco LLC designates this **enduring material** for a maximum of **.50** *AMA PRA Category 1 Credits*TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses (ANCC) Credit Designation**

Amedco LLC designates this activity for a maximum of **.50** ANCC contact hours.

**Pharmacists and Pharmacy Technicians (ACPE) Credit Designation**

Amedco LLC designates this activity for a maximum of **.50**  knowledge-based CPE contact hours.

**NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.**

###### Objectives - After Attending This Program You Should Be Able To

1. Understand the utility of novel biomarkers such as homologous repair deficiency (HRD) genomic instability for personalizing therapy in patients with ovarian cancer.
2. Assess the clinical rationale for tumor and HRD genomic instability testing, including differentiation of germline/familial risk assessment versus tumor profiling for therapeutic implications in ovarian cancer patients.
3. Be better prepared to monitor and manage adverse events for emerging targeted therapies for patients with and ovarian cancer.
4. Be more familiar with implementing strategies to improve engage patients in shared decision-making regarding biomarker testing and personalized treatment in ovarian cancer throughout the continuum of care starting at diagnosis.

**Disclosure of Conflict of Interest**

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5)

|  |  |  |  |
| --- | --- | --- | --- |
| **First** | **Last** | **Role** | **Commercial Interest** |
| William | Burke | Planner, Chair | NA |
| Robert | Coleman | Speaker, Planner | Abbvie:Research Grant Overall Principal Investigator,Amgen:Scientific/Medical Advisory Board Member,Clovis:Research Grant Overall Principal Investigator,Eisai:Scientific/Medical Advisory Board Member,Gsk:Scientific/Medical Advisory Board Member,Novocure:Scientific/Medical Advisory Board Member,Immunogen :Research Grant Overall Principal Investigator,Janssen:Research Grant Site Principal Investigator,Onxeo:Scientific/Medical Advisory Board Member,AstraZeneca :Scientific/Medical Advisory Board Member,Alkermes:Scientific/Medical Advisory Board Member,Oncomed:Scientific/Medical Advisory Board Member |
| Charles | Drescher | Planner | NA |
| John | Farley | Planning Committee | NA |
| Melissa | Hardesty | Speaker, Reviewer, Planner, Moderator, Planning Committee | AstraZeneca-Mereck:Consultant |
| Kate | Lally | No | No |
| Carolyn | Lefkowits | Yes | GSK: Speaker's Bureau |
| Jeff | Lin | Planning Committee | C-SATS/Johnson and Johnson:Consultant |
| Erin | Lips | Speaker | NA |
| Sandra | Megally | Planning Committee | NA |
| Roisin | O'Cearbhaill | Speaker, Planner, Moderator, Planning Committee | Bayer/Celgene/Juno:Scientific/Medical Advisory Board Member,Immunogen:Scientific/Medical Advisory Board Member,Fresenius Kabi:Scientific/Medical Advisory Board Member,SeaGen/Genmab:Scientific/Medical Advisory Board Member,GSK:Scientific/Medical Advisory Board Member,Regeneron:Scientific/Medical Advisory Board Member,MJH:Other,Curio Life Science:Other,Abbvie/TCR2/Atara Biotherapeutics/ GOG Foundation/StemCentryx/Regeneron/MarkerTherapeutics/Syndax/ Genmab/ Sellas Therapeutics/ Genentech:Research Grant Site Principal Investigator,Bayer/Celgene/Juno:Research Grant Overall Principal Investigator,Tesaro/GSK:Research Grant Site Principal Investigator,Ludwig Cancer Institute:Research Grant Site Principal Investigator |
| Michael | Pearl | Yes | LineaRX: Royalties |
| Aaron | Praiss | Speaker | NA |
| Tracy | Sandstrom | CE Coordinator | NA |
| Leigha | Senter-Jamieson | Planning Committee | Astrazeneca:Speakers Bureau,GSK:Scientific/Medical Advisory Board Member |
| Linda | Smith | No | No |
| Lori | Spoozak | No | No |
| Ashley | Stuckey | Planning Committee | NA |
| Premal | Thaker | Speaker, Planning Committee | Glaxo Smith Kline:Research Grant Site Principal Investigator,Glaxo Smith Kline:Scientific/Medical Advisory Board Member,Merck:Research Grant Site Principal Investigator,Merck:Scientific/Medical Advisory Board Member,Novocure:Scientific/Medical Advisory Board Member,Caris:Consultant,Astra Zeneca:Scientific/Medical Advisory Board Member,Celsion:Scientific/Medical Advisory Board Member,Celsion:Consultant,Celsion:Stock Shareholder,Eisai:Scientific/Medical Advisory Board Member,Seagen:Scientific/Medical Advisory Board Member |
| Todd | Tillmanns | Speaker, Reviewer, Planner | Myriad:Scientific/Medical Advisory Board Member,Eisai:Speakers Bureau,West Cancer Center Research Institute:Employee,GSK:Speakers Bureau,Astra Zeneca:Speakers Bureau,intuitive:Speakers Bureau |